THC-P vs Delta-8: Potency Claims, Evidence and Legal Status

THC-P and delta-8 differ in opposite directions from delta-9 THC. Delta-8 moves a double bond and binds the CB1 receptor more weakly, so it is less potent. THC-P keeps the delta-9 ring but has a longer seven-carbon side chain, and binds CB1 far more tightly in lab tests. Delta-8 has human trial data; THC-P has none, so its real-world strength is unmeasured.

Most pages ranking for “THC-P vs delta-8” repeat a potency multiplier for THC-P and then recommend starting with a small dose. The receptor figures are real, but they come from cell assays and mice, not people. Turning them into “times stronger” claims goes further than the evidence allows.

Below we set out the chemistry, what has been measured for each, safety and drug testing, and where both stand under the federal hemp redefinition. Background is in our glossary entries on THC-P and delta-8 THC.

At a glance

Property	THC-P	Delta-8 THC
Relationship to delta-9	Homologue: seven-carbon side chain instead of five	Isomer: double bond at carbon 8 instead of 9
Natural occurrence	Identified in a cannabis variety in 20191	Present in cannabis in small amounts
How products are made	Synthesised; often blended with other THC isomers8	Acid-catalysed conversion of hemp CBD
CB1 binding in the lab	Very strong; similar to potent synthetic agonist CP55,9401	Weaker than delta-93
Human trials	None found	Two controlled crossover trials (2025)4
Metabolism	Forms hydroxy and carboxy metabolites like delta-9 (in vitro)5	Forms less 11-OH metabolite than delta-94
Drug test	Blends often contain other THC; THC-P confirmable by LC-MS/MS6	Metabolites trigger standard urine screens
US federal status	Loses hemp status by 11 December 2026	Loses hemp status on 11 December 2026
UK status	Class B (covered by existing generic definition)12	Class B controlled drug

What THC-P and delta-8 are

Delta-9 THC has a five-carbon tail (the alkyl side chain) attached to its ring system. Delta-8 keeps that tail but has its double bond one position over. THC-P, short for tetrahydrocannabiphorol, keeps the delta-9 ring and extends the tail to seven carbons.

One reaction separates the two. Delta-8 is made by converting hemp CBD with acid and heat, which rearranges the ring. THC-P cannot be made that way from ordinary CBD, because CBD has the shorter five-carbon tail; the longer chain has to be built in from the start.

THC-P was identified in 2019 in a medicinal cannabis variety, along with its CBD counterpart, CBDP.¹ It is a genuine phytocannabinoid, but present in small amounts. Products sold as THC-P are synthesised. When forensic chemists analysed synthetically derived THC products sold between 2019 and 2024, several contained THC-P mixed with other THC isomers or HHC.⁸

One more wrinkle: seven-carbon homologues exist for both delta-9 and delta-8, and forensic methods now test for both.⁶ A label that says “THC-P” does not always say which one.

Why THC-P is described as stronger, and the limits of that claim

Side-chain length has long been known to affect how strongly THC-like molecules act on the CB1 receptor, the main target behind cannabis intoxication. In the 2019 study, THC-P bound human CB1 with an affinity (Ki 1.2 nM) similar to CP55,940 (Ki 0.9 nM), a potent synthetic full agonist. In mice, it produced the classic cannabinoid effects: reduced movement, reduced pain responses, catalepsy and lower body temperature.¹

A 2024 cell study comparing 30 THC-related compounds also found THC-P among those with a higher potential to activate CB1 than delta-9.² Delta-8 sits on the other side: a partial agonist with weaker CB1 affinity than delta-9.³

So the direction of the difference is well supported. The size is not. Binding affinity in a cell assay does not translate neatly into how intoxicated a person becomes, because absorption, metabolism and how fully the receptor is activated all intervene. Multipliers such as “30 times stronger”, common in marketing, are extrapolations from lab data, not measurements in people.

What delta-8 looks like in people

For delta-8 there are human data. In a 2025 double-blind trial of 19 adults, 20 mg of oral delta-8 produced weaker effects than 20 mg of delta-9, while 40 mg of delta-8 was indistinguishable from 20 mg of delta-9. Drug liking was similar across doses.⁴ Nothing comparable exists for THC-P.

How strong is the evidence?

• Delta-8: a substantial preclinical literature, controlled human trials, and several years of adverse event and poison centre data. Reasonable for short-term effects; weak for long-term use.
• THC-P: one discovery study with receptor and mouse data, later cell assays, and in vitro metabolism work using human liver enzymes.⁵ No human dosing studies. Very weak for anything about effects in people.

Real-world use appears to have outpaced the research. In an online survey of 229 US adults who used cannabis, published in 2026, 24.4% reported past-year THC-P use, slightly more than the 21.8% reporting delta-8, and adverse effects were reported for every semi-synthetic cannabinoid covered.⁷ Self-selected surveys cannot tell us how common or serious those effects are, but they show people are using THC-P without a human safety dataset.

What would settle the comparison? A controlled trial giving several doses of THC-P alongside delta-9 and placebo, with blood levels, impairment tests and heart-rate monitoring, as the 2025 delta-8 trials did. Until that exists, any statement that THC-P is a set number of times stronger than delta-8 is informed guesswork, however confidently it is presented.

Safety, side effects and drug testing

The main practical risk with THC-P is dosing uncertainty. If the lab data hold in people, small milligram amounts could produce strong effects, and many products are blends whose total THC content is hard to judge. Forensic analysis of synthetically derived gummies found 57 to 321 mg of total THC isomers per piece, and some products combined THC with THC-P or HHC.⁸

Reported side effects for both compounds are those of cannabis intoxication: anxiety or panic, paranoia, a racing heart, dizziness, nausea, drowsiness and impaired coordination. Edibles take longer to act, which increases the risk of redosing. Keep products away from children and pets, and do not drive after use.

Drug testing

In vitro work with human liver enzymes shows THC-P forms hydroxylated and carboxylated metabolites similar to those of delta-9, though at different rates.⁵ We found no published data on how strongly THC-P metabolites trigger standard urine immunoassays. That uncertainty offers little comfort: many THC-P products also contain delta-8 or delta-9, whose metabolites do trigger screens, and confirmation methods using LC-MS/MS can now identify THC-P in blood and urine.⁶

Anyone taking prescription medicines, with a history of psychosis or heart problems, or who is pregnant or breastfeeding should speak to a clinician before using any THC product.

Legal status in September 2026

THC-P and delta-8 both reached shelves through the 2018 Farm Bill definition of hemp, which only capped delta-9 THC. Congress has since rewritten that definition.

Section 781 of Public Law 119-37, enacted on 12 November 2025, takes effect on 12 November 2026.⁹ It switches to a total THC measure that includes THCA, and excludes finished products containing:

• cannabinoids “not capable of being naturally produced” by the cannabis plant;
• naturally occurring cannabinoids that were synthesised or manufactured outside the plant; or
• more than 0.4 mg per container of total THC combined with other cannabinoids that have, or are marketed to have, similar effects.

A one-month delay passed in September 2026 (H.R. 6500, section 2019) means only the first exclusion applies from 12 November; the rest, including the 0.4 mg cap, starts on 11 December 2026.¹⁰

Because delta-9 THC-P has been found in the plant, synthetic THC-P most naturally falls under the “manufactured outside the plant” wording from 11 December. A delta-8 homologue of THC-P may be treated differently if it is not considered naturally producible. The FDA lists meant to settle this had not been published as of August 2026.¹¹ Either way, THC-P products are marketed for THC-like effects and contain far more than 0.4 mg per container, so neither THC-P nor delta-8 products remain hemp after 11 December. Bills to delay or repeal the change sit in committee. Many states already ban both; see our state-by-state delta-8 guide.

UK: THC-P is already a Class B drug under the existing generic definition of cannabinol derivatives, according to the Advisory Council on the Misuse of Drugs, and delta-8 is also Class B.¹² Canada: the Cannabis Act covers phytocannabinoids and any identical substance however it is obtained, so both are treated as cannabis and may be sold only through licensed channels.

What to check on a label or COA

Where these products are still sold legally, the certificate of analysis is the only independent record of what is inside. Our explainer on the hemp COA covers the basics. For THC-P and delta-8 products, look for:

• THC-P reported in milligrams, not just “present”. Many blends list THC-P as a small fraction of the total. You need the actual amount per piece or per millilitre.
• Which THC-P. Ideally the COA distinguishes delta-9-THCP from delta-8-THCP.
• Every other cannabinoid in the blend. Delta-8, delta-9, delta-10 and HHC often appear together; add them up to understand the total THC load.
• Residual solvents and heavy metals. Synthesis and conversion both use solvents, acids and sometimes metal catalysts.
• Batch match and accreditation. The COA should match the batch on the pack and come from an ISO/IEC 17025 accredited lab.

For how delta-8 compares with delta-9 in more detail, see our delta-8 vs delta-9 comparison.

Frequently asked questions

How much stronger is THC-P than delta-8?

Nobody has measured it in people. THC-P binds the CB1 receptor about as tightly as a potent synthetic cannabinoid in lab tests,¹ while delta-8 binds more weakly than delta-9.³ That suggests THC-P is considerably stronger per milligram, but popular multipliers are extrapolations from cell and mouse data, not human trial results.

Is THC-P natural or synthetic?

Both, in a sense. Delta-9 THC-P was identified in a cannabis variety in 2019, so it is a real phytocannabinoid.¹ It occurs only in small amounts, however, and THC-P sold in vapes and gummies is synthesised in a lab and often blended with other THC isomers.⁸

Does THC-P show up on a drug test?

Assume it will. THC-P is metabolised into hydroxy and carboxy compounds similar to those from delta-9,⁵ many THC-P products also contain delta-8 or delta-9, which trigger standard urine screens, and laboratories can confirm THC-P specifically using LC-MS/MS.⁶ Data on how standard screening kits respond to THC-P alone are lacking.

Is THC-P legal in 2026?

Under US federal law, THC-P products lose hemp status by 11 December 2026, when the 0.4 mg per container cap and the ban on cannabinoids manufactured outside the plant take effect.¹⁰ Many states already prohibit it. In the UK, THC-P is a Class B controlled drug.¹²

Why is THC-P often sold in blends?

Forensic analysis of products sold between 2019 and 2024 found THC-P combined with other THC isomers or HHC.⁸ Blending makes the total effect hard to predict: you are taking several intoxicating cannabinoids at once, with no human data on how they combine. Check the certificate of analysis for the amount of every component, not just the headline cannabinoid.

Sources

1. Citti C, Linciano P, Russo F, et al.. A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol. Sci Rep. 2019;9(1):20335. DOI: 10.1038/s41598-019-56785-1. PMID: 31889124. pubmed.ncbi.nlm.nih.gov
2. Janssens LK, Van Uytfanghe K, Williams JB, Hering KW, Iula DM, Stove CP. Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays-and how this matters for the harm potential of seized drugs. Arch Toxicol. 2024;98(8):2619-2630. DOI: 10.1007/s00204-024-03769-4. PMID: 38735004. pubmed.ncbi.nlm.nih.gov
3. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol (Δ8-THC): Comparative pharmacology with Δ9-THC. Br J Pharmacol. 2022;179(15):3915-3933. DOI: 10.1111/bph.15865. PMID: 35523678. pubmed.ncbi.nlm.nih.gov
4. Zamarripa CA, Spindle TR, Schriefer D, et al.. A within-subject cross-over trial comparing the acute effects of oral delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in healthy adults. Drug Alcohol Depend. 2025;272:112676. DOI: 10.1016/j.drugalcdep.2025.112676. PMID: 40288059. pubmed.ncbi.nlm.nih.gov
5. James KM, Poklis JL, Karschner EL, Dempsey SK, Peace MR. Delta-9-tetrahydrocannabutol, delta-9-tetrahydrocannabihexol, and delta-9-tetrahydrocannabiphorol: the impact of varying alkyl chain length on delta-9-tetrahydrocannabinol analog metabolism. J Anal Toxicol. 2026;50(8):bkag045. DOI: 10.1093/jat/bkag045. PMID: 42286420. pubmed.ncbi.nlm.nih.gov
6. Muir LS, Doumit SE, Seither JZ, Knittel JL, Walterscheid JP, Karschner EL. Comprehensive LC-MS-MS analysis of THC isomers, analogs, homologs, and metabolites in blood and urine. J Anal Toxicol. 2025;49(5):322-331. DOI: 10.1093/jat/bkaf023. PMID: 40098275. pubmed.ncbi.nlm.nih.gov
7. Pabon E, Lake S, Murray CH, Cooper ZD. Emerging Hemp-Derived Semi-Synthetic Cannabinoids, Absent Regulations: Patterns of Use and Adverse Effects Among a Sample of U.S. Cannabis Consumers. Cannabis Cannabinoid Res. 2026;11(5):396-404. DOI: 10.1177/25785125251391987. PMID: 41335500. pubmed.ncbi.nlm.nih.gov
8. Ciolino LA, Ranieri TL. HPLC-UV quantitation of synthetically derived THC, THCP, and HHC isomers in commercial vaping liquids and edibles (2019-2024). J Forensic Sci. 2026 (online ahead of print). DOI: 10.1111/1556-4029.70408. PMID: 42748050. pubmed.ncbi.nlm.nih.gov
9. U.S. Congress. Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. Public Law 119-37 (H.R. 5371), Division B, Section 781, amending section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o). Enacted 12 November 2025. govinfo.gov
10. U.S. Congress. Continuing Appropriations and Extensions Act, 2027. H.R. 6500 (enrolled bill), Section 2019, “Section 781 Extension”. 2026. govinfo.gov
11. Congressional Research Service. Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy. In Focus IF13136. Updated August 2026. congress.gov
12. Advisory Council on the Misuse of Drugs. ‘Semi-synthetic’ Cannabinoids: Cannabinoids related to tetrahydrocannabinol and cannabidiol. Report and cover letter to the Minister of State, 22 May 2025. gov.uk

Editorial note: This article is for general information only and is not medical or legal advice. THC-P and delta-8 THC have not been evaluated by the FDA to diagnose, treat, cure or prevent any disease. Laws vary by location and change often, so verify the rules that apply where you are. Always talk to a licensed healthcare provider before use, especially if you are under 21, pregnant or nursing, taking medication, or managing a health condition.